πŸ‡ΊπŸ‡Έ FDA

Intelligence Β· Patent portfolio

Regeneron Ireland Designated Patents

Full USPTO pharma patent portfolio for Regeneron Ireland Designated β€” grant dates, expiration, and drug cross-links.

Patents
8,292
Expiring ≀24m
426

Quick answer

Regeneron Ireland Designated has 8,292 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 426 expire within 24 months β€” use filters for patent-cliff planning.

Page 123 of 173

  1. US 7927613

    Pharmaceutical co-crystal compositions

    Expires Mon Apr 14 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 7927833

    Composition and method for enhancing immune response

    Expires Mon Apr 14 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 7928080

    Indole antiviral compositions and methods

    Expires Mon Apr 14 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 7928213

    Nucleic acids encoding chimeric CD154 polypeptides

    Expires Mon Apr 14 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 7922999

    Administration of growth factors for the treatment of CNS disorders

    Expires Mon Apr 07 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 7923548

    Inhibition of chronic myelogenous leukemic cell growth by liposomal-antisense oligodeoxy-nucleotides targeting to Grb2 or Crk1

    Expires Mon Apr 07 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 7923014

    Expression and purification of HIP/PAP and uses therefor

    Expires Mon Apr 07 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 7923010

    Methods and materials for treating autoimmune diseases and conditions

    Expires Mon Apr 07 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 7923001

    Compositions and methods for diagnosing and treating urinary tract infections

    Expires Mon Apr 07 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 7919613

    RNAi modulation of SCAP and therapeutic uses thereof

    Expires Mon Mar 31 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 7919108

    Taxane coatings for implantable medical devices

    Expires Mon Mar 31 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 7919475

    Compositions and methods for improving heart function

    Expires Mon Mar 31 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 7919579

    Imaging and therapeutic targeting of prostate and bladder tissues

    Expires Mon Mar 31 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 7919079

    Cancer immunotherapy compositions and methods of use

    Expires Mon Mar 31 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 7919466

    Lymphatic zip codes in tumors and pre-malignant lesions

    Expires Mon Mar 31 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 7919588

    Netrin receptors

    Expires Mon Mar 31 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 7919636

    Purifications of pomegranate ellagitannins and their uses thereof

    Expires Mon Mar 31 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 7919088

    Treatment and delay of onset of synucleinopathic and amyloidogenic disease

    Expires Mon Mar 31 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 7915245

    Methods and compositions of trail-death receptor agonists/activators

    Expires Mon Mar 24 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 7915025

    In vivo incorporation of unnatural amino acids

    Expires Mon Mar 24 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 7915285

    Method for treating drug and behavioral addictions

    Expires Mon Mar 24 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 7914780

    Aminopeptidase A (APA) targeting peptides for the treatment of cancer

    Expires Mon Mar 24 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 7910299

    Methods for diagnosing systemic lupus erythematosus

    Expires Mon Mar 17 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 7910323

    Methods for identifying the effect of a drug agent on the metabolism of sugars and fats in an individual

    Expires Mon Mar 17 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 7910621

    Small molecule antagonists of XIAP family proteins

    Expires Mon Mar 17 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 7906555

    Aquaporin modulators and methods of using them for the treatment of edema and fluid imbalance

    Expires Mon Mar 10 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 7906628

    Targeting proteins to deliver therapeutic or diagnostic reagents

    Expires Mon Mar 10 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 7906638

    Chimeric nucleic acids encoding polypeptides comprising CD70 and Fas ligand domains

    Expires Mon Mar 10 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 7906962

    Dynamic nuclear polarization enhanced nuclear magnetic resonance of water under ambient conditions

    Expires Mon Mar 10 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 7906104

    Methods for detecting pancreatic beta-islet cells and diseases thereof

    Expires Mon Mar 10 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 7901453

    Coated implantable medical device

    Expires Mon Mar 03 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 7902166

    Compositions comprising inhibitors of RNA binding proteins and methods of producing and using same

    Expires Mon Mar 03 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 7897340

    Use of tumor susceptibilty gene 101 (TSG 101) as a prognostic and diagnostic marker

    Expires Mon Feb 24 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 7896914

    Coated implantable medical device

    Expires Mon Feb 24 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 7897791

    Purifications of pomegranate ellagitannins and their uses thereof

    Expires Mon Feb 24 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 7897588

    Agents and methods for enhancing bone formation

    Expires Mon Feb 24 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 7893033

    Targeting proteins to deliver therapeutic or diagnostic reagents

    Expires Mon Feb 17 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 7893299

    Interleukin-1 and tumor necrosis factor-Ξ±modulators; syntheses of such modulators and methods of using such modulators

    Expires Mon Feb 17 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 7893027

    Treatment of ocular wounds and ulcers

    Expires Mon Feb 17 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 7892554

    Internalizing ErbB2 antibodies

    Expires Mon Feb 17 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 7892567

    Methods and compositions for immunization against chlamydial infection and disease

    Expires Mon Feb 17 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 7892539

    Modulation of an innate immune response by altering TRIAL-R signaling

    Expires Mon Feb 17 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 7892777

    Methods for measuring whether a treatment affects RPTP-ΞΊ activity

    Expires Mon Feb 17 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 7887836

    Compositions and methods for treating lymphoma

    Expires Mon Feb 10 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 7887829

    Mucosal cell composites and methods

    Expires Mon Feb 10 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 7888389

    Tetrapropylammonium tetrathiomolybdate and related compounds for anti-angiogenic therapies

    Expires Mon Feb 10 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 7888372

    Compositions and methods for modulating bone mineral deposition

    Expires Mon Feb 10 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 7888332

    Hydrazide-containing CFTR inhibitor compounds and uses thereof

    Expires Mon Feb 10 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many patents does Regeneron Ireland Designated have?

8,292 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).

When do Regeneron Ireland Designated patents expire?

426 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.

Where does this data come from?

USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.

Data attribution: Data sources Β· Patent directory

Drug approvals, clinical trials, M&A, event intelligence, and company updates β€” weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.